You're signed outSign in or to get full access.
Baker Bros. Advisors LP
Baker Bros. Advisors LP is a hedge fund and registered investment adviser headquartered in New York City, founded in 2000 by Julian Baker and Felix Baker. The firm specializes in investments within the biotechnology, life sciences, and healthcare sectors, managing multi-billion dollar portfolios predominantly focused on publicly traded US healthcare companies. Serving institutional and high-net-worth investors, the firm is recognized as one of the most successful healthcare-focused investment managers in the United States.
Investment Strategy
Baker Bros. Advisors employs a fundamentally driven, long-term investment approach with a focus on biotechnology and life sciences companies. The firm invests primarily in public and private healthcare-related securities, including equities, warrants, and convertible debt, concentrating capital in a select group of high-conviction investments. Their strategy involves detailed scientific and financial due diligence, often taking activist or influential roles to support portfolio companies, aiming for superior risk-adjusted returns in the sector.
Latest 13F Filing Activity
Baker Bros. Advisors LP filed their most recent 13F report on Jun 30, 2025 disclosing 87 equity positions with a total 13F market value of $10B. The fund increased holdings in Insmed Incorporated, Summit Therapeutics Inc., Incyte Corporation among other positions. Baker Bros. Advisors LP reduced exposure to Madrigal Pharmaceuticals, Inc., Edgewise Therapeutics, Inc., Argenx SE among others.
Top Holdings
Equity Positions (87)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
I INCY | Incyte Corporation | 20.31% | $2.09B | 30,743,275 | $73.57 | $68.10 | +$232.3M |
A ACAD | ACADIA Pharmaceuticals Inc. | 8.98% | $925.3M | 42,896,690 | $15.77 | $21.57 | +$213.1M |
I INSM | Insmed Incorporated | 7.53% | $776.2M | 7,712,900 | $75.94 | $100.64 | +$365.7M |
S SMMT | Summit Therapeutics Inc. | 6.96% | $717.6M | 33,722,974 | $12.25 | $21.28 | +$246.5M |
M MDGL | Madrigal Pharmaceuticals, Inc. | 5.80% | $598.0M | 1,976,018 | $173.16 | $302.64 | -$56.0M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more